Quest Diagnostics Inc (DGX) receives a weak valuation ranking of 30 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. DGX has a better value than 30% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
DGX gets a 30 Valuation Rank today. Find out what this means to you and get the rest of the rankings on DGX!
DGX's trailing-12-month Price to Earnings (PE) ratio of 18.51 puts it around the historical average of roughly 15. DGX is a average value at its current trading price as investors are paying around what its worth in relation to the company's earnings. DGX's trailing-12-month earnings per share (EPS) of 7.96 does justify what it is currently trading at in the market. Trailing PE ratios, however, do not factor in a company's projected growth rate, resulting in some firms having high PE ratios due to high growth potentially enticing investors even if current earnings are low.
DGX's 12-month-forward PE to Growth (PEG) ratio of 2.8 is considered a poor value as the market is overvaluing DGX in relation to the company's projected earnings growth due. DGX's PEG comes from its forward price to earnings ratio being divided by its growth rate. A PEG ratio of 1 represents a perfect correlation between earnings growth and share price. Due to their incorporation of more fundamentals of a company's overall health and focusing on the future rather than the past, PEG ratios are one of the most used valuation metrics by analysts today.
